Engineering a Novel Antibody-Peptide Bispecific Fusion Protein Against MERS-CoV
In recent years, tremendous efforts have been made in the engineering of bispecific or multi-specific antibody-based therapeutics by combining two or more functional antigen-recognizing elements into a single construct. However, to the best of our knowledge there has been no reported cases of effect...
Main Authors: | Lili Wang, Jiyan Xu, Yu Kong, Ruiying Liang, Wei Li, Jinyao Li, Jun Lu, Dimiter S. Dimitrov, Fei Yu, Yanling Wu, Tianlei Ying |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2019-11-01
|
Series: | Antibodies |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4468/8/4/53 |
Similar Items
-
In Vivo Secretion of Bispecific Antibodies Recruiting Lymphocytic Effector Cells
by: Luis Alvarez-Vallina, et al.
Published: (2013-06-01) -
Design and Production of Bispecific Antibodies
by: Qiong Wang, et al.
Published: (2019-08-01) -
Development of Small-Molecule MERS-CoV Inhibitors
by: Ruiying Liang, et al.
Published: (2018-12-01) -
Efficacy of a Bispecific Antibody Co-Targeting VEGFA and Ang-2 in Combination with Chemotherapy in a Chemoresistant Colorectal Carcinoma Xenograft Model
by: Thomas Mueller, et al.
Published: (2019-08-01) -
Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies
by: Zheng Tian, et al.
Published: (2021-05-01)